U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H37N5O9
Molecular Weight 467.5145
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOBRAMYCIN

SMILES

NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O

InChI

InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N
InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI
Molecular Formula C18H37N5O9
Molecular Weight 467.5145
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 14 / 14
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Poor penetrability of tobramycin through the blood-CSF barrier was shown.

Originator

Stark, W.M.|Hoehn, M.M.|Knox, N.G.
4
Curator's Comment: Tobramycin is the generic ingredient in eleven branded drugs marketed by Amneal Pharms, Chiesi Usa Inc, Akorn Inc, Fera Pharms, Pulmoflow Inc, Alcon, Alcon Labs Inc, Bausch And Lomb, Novartis Pharms, Alcon Pharms Ltd, Apotex Inc, Novartis, Teva Pharms Usa, Akorn, Lilly, Mylan Labs Ltd, Hospira, Hikma Maple , X Gen Pharms, Igi Labs Inc, Fresenius Kabi Usa, Apothecon, Watson Labs Inc, and Xellia Pharms Aps, and is included in forty-five NDAs. Nebramycin, an antibiotic complex of at least seven factors, was first described in 1967 by Stark et al.

Approval Year

1975
63
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 9.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
TOBREX

Approved Use

external infections of the eye

Launch Date

1980
Primary
Approved
8583
KITABIS PAK

Approved Use

cystic fibrosis

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/4208289/
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
814 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN sputum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.6 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/4208289/
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/4208289/
80 mg single, intramuscular
dose: 80 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TOBRAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN sputum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf
300 mg single, respiratory
dose: 300 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
TOBRAMYCIN sputum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6440126
unhealthy, 2 months - 27 years
Health Status: unhealthy
Age Group: 2 months - 27 years
Sources:
https://pubmed.ncbi.nlm.nih.gov/6440126
Sources:
https://pubmed.ncbi.nlm.nih.gov/6440126
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Other AEs: Forced expiratory volume decreased, Rales...
Other AEs:
Forced expiratory volume decreased (31%)
Rales (19%)
Red blood cell sedimentation rate increased (8%)
Dysphonia (6%)
Wheezing (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Other AEs: Hypersensitivity, Eyelids itchy sensation of...
Other AEs:
Hypersensitivity
Eyelids itchy sensation of
Swelling
Redness of eyelid conjunctiva
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
1.5 mg/kg 3 times / day multiple, intramuscular
Dose: 1.5 mg/kg, 3 times / day
Route: intramuscular
Route: multiple
Dose: 1.5 mg/kg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/820195
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/820195
Sources:
https://pubmed.ncbi.nlm.nih.gov/820195
2 mg/kg single, intraperitoneal
Dose: 2 mg/kg
Route: intraperitoneal
Route: single
Dose: 2 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3950451
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/3950451
Sources:
https://pubmed.ncbi.nlm.nih.gov/3950451
AEs

AEs

AESignificanceDosePopulation
Rales 19%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Forced expiratory volume decreased 31%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Wheezing 5%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Dysphonia 6%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Red blood cell sedimentation rate increased 8%
300 mg 2 times / day multiple, respiratory
Recommended
Dose: 300 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
unhealthy, >6 years
Health Status: unhealthy
Age Group: >6 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Eyelids itchy sensation of
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Hypersensitivity
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Redness of eyelid conjunctiva
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Swelling
3 mg 3 times / day multiple, ophthalmic
Recommended
Dose: 3 mg, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741

OAT1
725

OAT3
747

OAT2
153

OATP1B1
1079

OATP2B1
157

OCT1
620

OCT2
779
P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
1095
 minor
OCT1
656
 minor
OCT2
782
 minor
OAT2
155
 no
OATP2B1
162
 no
P-gp
1932
 no
OAT1
730
 yes
OAT3
749
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28864
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28864
ChemicalBook
CB7154445
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7154445
eMolecules
36516853
https://www.emolecules.com/cgi-bin/more?vid=36516853
eMolecules
3716283
https://www.emolecules.com/cgi-bin/more?vid=3716283
MolPort
MolPort-003-665-548
https://www.molport.com/shop/molecule-link/MolPort-003-665-548
Selleck Chemicals
Tobramycin(free-base)
http://www.selleckchem.com/products/Tobramycin(free-base).html
ZINC
ZINC000008214692
http://zinc15.docking.org/substances/ZINC000008214692
PubMed

PubMed

TitleDatePubMed
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.
2001-11-01
Gene expression in Pseudomonas aeruginosa biofilms.
2001-10-25
High-rising terminals and fall-rise tunes in Australian English.
2001-10-20
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.
2001-10
The treatment of cystic fibrosis--step by step.
2001-10
Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture.
2001-10
Bacillus cereus keratitis associated with contact lens wear.
2001-10
Efficacy and safety of aerosolized tobramycin in cystic fibrosis.
2001-10
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
2001-10
Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs.
2001-10
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
2001-09-22
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.
2001-09
Isolation and culture of airway epithelial cells from chronically infected human lungs.
2001-09
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].
2001-09
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin.
2001-09
Recovery from vestibular ototoxicity.
2001-09
Defining a pulmonary exacerbation in cystic fibrosis.
2001-09
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.
2001-09
Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial.
2001-09
Microbiological and immunologic considerations with aerosolized drug delivery.
2001-09
Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.
2001-09
Administration of aerosolized antibiotics in cystic fibrosis patients.
2001-09
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
2001-09
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.
2001-09
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
2001-08-02
The role of nebulized antibiotics in treating serious respiratory infections.
2001-08
Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site.
2001-08
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
2001-08
Mycobacterium keratitis following hyperopic laser in situ keratomileusis.
2001-08
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.
2001-08
In vitro elution of tobramycin from bioabsorbable polycaprolactone beads.
2001-08
Serratia Marcescens corneal ulcer as a complication of orthokeratology.
2001-08
Selective decontamination of the digestive tract in severely burned pediatric patients.
2001-08
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001-07-30
Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.
2001-07-09
[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
2001-07
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
2001-07
Recent advances in cystic fibrosis.
2001-07
In vitro selection of RNA against kanamycin B.
2001-06-30
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).
2001-06
Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement.
2001-06
Clinical observation and treatment of leptospirosis.
2001-06
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.
2001-06
[Cloning of the sugar related biosynthesis gene cluster from Streptomyces tenebrarius H6].
2001-05
Natural antibiotic susceptibility of recently established coryneform bacteria.
2001-05
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus].
2001-05
Risk of endotoxemia during the initial phase of gut decontamination with antimicrobial agents.
2001-03
New and emerging therapies for pulmonary complications of cystic fibrosis.
2001
Aerosols and anti-infectious agents.
2001
Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit.
2001
Patents

Patents

2414737
4
5149694
4
5508269
4
JP2002038183A
4
JP2002253216A
7
JP2003050204A
4
JP2003515526A
470
JP2004026827A
11
JP2005168352A
7
JP2006523695A
7
JP2007301214A
5
JP2007503292A
4
JP2008539832A
84
JP2009519467A
53
JP2009525790A
103
JP2010510030A
4
JP4668206B2
4
JP4689938B2
4
JPH02286627A
4
JPH0429930A
8
JPH07309763A
4
JPH08231405A
4
JPS5557598A
4

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Tobramycin does not pass the gastro-intestinal tract, so for systemic use it can only be given intravenously or intramuscularly http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/063111s014lbl.pdf. Dosage is different for different infections. Ophthalmic route of administration is also possible, as indicated here http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails or for TOBREX http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050541s024lbl.pdf
KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.
Route of Administration: Respiratory
In Vitro Use Guide
Curator's Comment: Low dose tobramycin (4 ug/ml) as a single agent was bactericidal against only 16% of Pseudomonas aeruginosa isolates; however, 72% of isolates were killed with high-dose tobramycin (200 ug/ml).
High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:01:25 GMT 2025
Edited
by admin
on Mon Mar 31 18:01:25 GMT 2025
Record UNII
VZ8RRZ51VK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOBRAMYCIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TOBRADEX COMPONENT TOBRAMYCIN
Preferred Name English
TOBRAMYCIN [ORANGE BOOK]
Common Name English
TOBRASONE COMPONENT TOBRAMYCIN
Common Name English
TOBRAMYCIN [USP MONOGRAPH]
Common Name English
ZYLET COMPONENT TOBRAMYCIN
Common Name English
TOBRAMYCIN [EP MONOGRAPH]
Common Name English
TOBREX
Brand Name English
TOBRAMYCIN [JAN]
Common Name English
TOBRAMYCIN [HSDB]
Common Name English
tobramycin [INN]
Common Name English
NEBRAMYCIN VI
Common Name English
TOBRAMYCIN [MI]
Common Name English
TOBRADEX ST COMPONENT TOBRAMYCIN
Common Name English
AKTOB
Brand Name English
NEBRAMYCIN FACTOR 6
Common Name English
TOBRAMYCIN [VANDF]
Common Name English
47663
Code English
KITABIS PAK
Brand Name English
D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-
Common Name English
VANTOBRA
Brand Name English
O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE
Common Name English
TOBI PODHALER
Brand Name English
NSC-180514
Code English
TOBRAMYCIN [USAN]
Common Name English
TOBRAMYCIN [MART.]
Common Name English
TOBRAMYCIN [USP-RS]
Common Name English
Tobramycin [WHO-DD]
Common Name English
TOBI
Brand Name English
Classification Tree Code System Code
NDF-RT N0000007853
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
NCI_THESAURUS C2363
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
WHO-ATC S01AA12
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
WHO-VATC QJ01GB01
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
EU-Orphan Drug EU/3/06/366
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
FDA ORPHAN DRUG 84494
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
LIVERTOX NBK548505
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
WHO-VATC QS01AA12
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
FDA ORPHAN DRUG 271908
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
FDA ORPHAN DRUG 278009
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
CFR 21 CFR 862.3900
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
WHO-ATC J01GB01
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
NDF-RT N0000175477
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
FDA ORPHAN DRUG 281709
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
EMA ASSESSMENT REPORTS VANTOBRA (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
EMA ASSESSMENT REPORTS TOBI PODHALER (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
FDA ORPHAN DRUG 121098
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
Code System Code Type Description
NSC
180514
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
CAS
32986-56-4
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023680
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
LACTMED
Tobramycin
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
NCI_THESAURUS
C62082
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
RS_ITEM_NUM
1667508
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
INN
2990
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
CHEBI
73678
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
PUBCHEM
36294
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
FDA UNII
VZ8RRZ51VK
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
EVMPD
SUB11134MIG
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
MESH
D014031
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
DAILYMED
VZ8RRZ51VK
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
ECHA (EC/EINECS)
251-322-5
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL1747
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
CHEBI
28864
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
DRUG CENTRAL
2684
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
RXCUI
10627
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
TOBRAMYCIN
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
MERCK INDEX
m10917
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY Merck Index
HSDB
3259
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
SMS_ID
100000091065
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
DRUG BANK
DB00684
Created by admin on Mon Mar 31 18:01:25 GMT 2025 , Edited by admin on Mon Mar 31 18:01:25 GMT 2025
PRIMARY
Related Record Type Details
Structure of TOBRAMYCIN SULFATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
ROUTE OF ADMINISTRATION: INJECTION
BINDING
Related Record Type Details
Structure of NEAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BEKANAMYCIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NEBRAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of TOBRAMYCIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC BIOLOGICAL ROUTE OF ADMINISTRATION: INJECTION

SUSCEPTIBILITY: RESISTANT

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES ? 1200 GRAMS

Tmax PHARMACOKINETIC DOSAGE FORM: POWDER

ROUTE OF ADMINISTRATION: ORAL INHALATION

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: CHILDREN

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: NEONATES

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC DOSAGE FORM: POWDER

ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life PHARMACOKINETIC POPULATION: NEONATES ? 1200 GRAMS

MIC BIOLOGICAL PATHOGEN: LOW ORDER OF ACTIVITY AGAINST MOST GRAM-POSITIVE ORGANISMS INCLUDING S. PNEUMONIAE, S. PYOGENES, AND ENTEROCOCCI

SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. AUREUS, CITROBACTER spp., ENTEROBACTER spp., E. COLI, KLEBSIELLA spp., MORGANELLA MORGANII, P. AEURUGINOSA, P. MIRABILIS, PROTEUS VULGARIS, PROVIDENCIA spp., SERRATIA spp.

ROUTE OF ADMINISTRATION: INJECTION

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: IM

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: INFANTS

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL INHALATION

DOSAGE FORM: POWDER

POPULATION: TYPICAL CYSTIC FIBROSIS PATIENTS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH IMPAIRED RENAL FUNCTION

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: IIV

Biological Half-life PHARMACOKINETIC DOSAGE FORM: SOLUTION

ROUTE OF ADMINISTRATION: ORAL INHALATION

Biological Half-life PHARMACOKINETIC POPULATION: ADOLESCENTS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

ROUTE OF ADMINISTRATION: INJECTION

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

POPULATION: ADULTS

Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION: INJECTION

POPULATION: ADOLESCENTS

NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966